aCGH provides an alternative means of genome-wide screening for copy number variations. First developed to detect copy number changes in solid tumors, CGH uses two genomes, a test and a control, which are differentially labeled and competitively hybridized to metaphase chromosomes. The fluorescent signal intensity of the labeled test DNA relative to that of the reference DNA can then be linearly plotted across each chromosome, allowing the identification of copy number changes. (Theisen, A. (2008) Microarray-based comparative genomic hybridization (aCGH). Nature Education 1(1) : 45)
Preimplantation Genetic Screening (PGS) with aCGH is the comprehensive and accurate assessment of all 24 chromosomes from an embryo biopsy. Using 24 Sure Microarray from Illumina TM, this arrays can be used to screen for aneuploidy in first and second polar bodies, blastomere biopsies, and trophectoderm biopsies. The 24sure assay is objective, ensuring a high degree of confidence in the results and subsequent selection of euploid embryos for transfer.
• Widely used, proven PGS : Method of choice for many of the world’s reference laboratories; used to process over 350,000 samples
• Fast, reliable results : Comprehensive, accurate assessment of all 24 chromosomes in 12 hours
• Straightforward Workflow : Optimized protocols include minimal tube transfers, documented QC stages, and flexible stopping points
Straightforward Workflow Is Complete in 12 Hours
The straightforward 24sure protocol used standard laboratory techniques, providing a fast, accurate method for chromosome screening with minimal sensitivity to technical errors and designed to fit into existing workflows. Screening can be completed in 12 hours, and therefore does not interfere with tight schedules of a fresh IVF cycle.
24 sure microarrays are provided as part of a pack that includes reagents for comprehensive chromosome screening of a single or few embryonic cells using the 24sure single-channel protocol.